Tailoring the AAV vector capsid for gene therapy
- PMID: 19052631
- DOI: 10.1038/gt.2008.170
Tailoring the AAV vector capsid for gene therapy
Abstract
A number of preclinical studies have shown the adeno-associated virus (AAV) to be an efficient vehicle for gene therapy. Clinical studies successfully demonstrated its potential for in vivo gene transfer. The complexity of host-vector interactions when progressing from small to large animal models, and eventually to humans, has impeded translation of AAV technology to the clinic. One approach to address this complexity has been to explore the biological characteristics of variations in AAV capsid structure. Initial strategies characterized the naturally occurring capsid variants from mammalian species. The structural and functional knowledge gathered on these natural AAV variants as vectors has led to the first series of second-generation vectors that aim at specifically improving certain properties by rational design of the capsid. A third exciting approach uses directed evolution to isolate vectors that are able to overcome selective pressures applied in the laboratory and thereby steer the capsid to evolve toward improved functionality.
Similar articles
-
Recent developments in adeno-associated virus vector technology.J Gene Med. 2008 Jul;10(7):717-33. doi: 10.1002/jgm.1205. J Gene Med. 2008. PMID: 18452237 Review.
-
Receptor targeting of adeno-associated virus vectors.Gene Ther. 2003 Jul;10(14):1142-51. doi: 10.1038/sj.gt.3301976. Gene Ther. 2003. PMID: 12833123 Review.
-
Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.Methods Mol Biol. 2011;709:127-39. doi: 10.1007/978-1-61737-982-6_8. Methods Mol Biol. 2011. PMID: 21194025
-
Adeno-associated virus serotypes: vector toolkit for human gene therapy.Mol Ther. 2006 Sep;14(3):316-27. doi: 10.1016/j.ymthe.2006.05.009. Epub 2006 Jul 7. Mol Ther. 2006. PMID: 16824801 Review.
-
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.Gene Ther. 2008 Jun;15(11):808-16. doi: 10.1038/gt.2008.54. Epub 2008 Apr 3. Gene Ther. 2008. PMID: 18385765 Review.
Cited by
-
Synthetic DNA vaccine strategies against persistent viral infections.Expert Rev Vaccines. 2013 May;12(5):537-54. doi: 10.1586/erv.13.33. Expert Rev Vaccines. 2013. PMID: 23659301 Free PMC article. Review.
-
Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.J Immunother. 2015 Sep;38(7):292-8. doi: 10.1097/CJI.0000000000000093. J Immunother. 2015. PMID: 26261893 Free PMC article.
-
Reversed Phase-Liquid Chromatography for Recombinant AAV Genome Integrity Assessment.Anal Chem. 2023 Jun 6;95(22):8478-8486. doi: 10.1021/acs.analchem.3c00222. Epub 2023 May 23. Anal Chem. 2023. PMID: 37219094 Free PMC article.
-
New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets.iScience. 2024 Apr 18;27(5):109777. doi: 10.1016/j.isci.2024.109777. eCollection 2024 May 17. iScience. 2024. PMID: 38711458 Free PMC article.
-
Repression of cardiac hypertrophy by KLF15: underlying mechanisms and therapeutic implications.PLoS One. 2012;7(5):e36754. doi: 10.1371/journal.pone.0036754. Epub 2012 May 7. PLoS One. 2012. PMID: 22586493 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical